Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Alpha-9 Oncology USA Inc.
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Ankyra Therapeutics, Inc
Pfizer
Boehringer Ingelheim
MonTa Biosciences ApS
ViroMissile, Inc.
Yale University
National Institutes of Health Clinical Center (CC)
Tizona Therapeutics, Inc
Genentech, Inc.
Shanghai Henlius Biotech
Ohio State University Comprehensive Cancer Center
Icahn School of Medicine at Mount Sinai
Incyte Corporation
MacroGenics
Memorial Sloan Kettering Cancer Center
Pfizer
US Dermatology Partners, Phoenix
University of Florida
Conjupro Biotherapeutics, Inc.
Immatics US, Inc.
Innate Pharma
H. Lee Moffitt Cancer Center and Research Institute
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
OncoNano Medicine, Inc.
Memorial Sloan Kettering Cancer Center
Compass Therapeutics
Memorial Sloan Kettering Cancer Center
LG Chem
West China Hospital
Adze Biotechnology Inc
M.D. Anderson Cancer Center
Nested Therapeutics, Inc
Modulation Therapeutics, Inc.
St. Jude Children's Research Hospital
TuHURA Biosciences, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
Treeline Biosciences, Inc.
Mayo Clinic
Novelty Nobility, Inc.
SciTech Development, Inc.
Rutgers, The State University of New Jersey
Washington University School of Medicine
UNC Lineberger Comprehensive Cancer Center